Imugene Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IUGNF research report →
About the company
Imugene Limited, an Australian firm specializing in clinical-stage immuno-oncology, is dedicated to conceiving diverse immunotherapies. Its core mission involves activating the immune systems of cancer patients to effectively combat and eradicate malignant growths. The company's primary therapeutic candidate is HER-Vaxx, a vaccine engineered for HER2-positive cancers.
- CEO
- Leslie Chong
- IPO
- 2019
- Employees
- 5
- HQ
- Sydney, NSW, AU
Price Chart
- Market Cap
- $33.27M
- P/E
- -0.60
- P/S
- 17.89
- P/B
- 0.94
- EV/EBITDA
- -0.80
- Div Yield
- 0.00%
- Gross Margin
- -65.91%
- Op Margin
- -1960.77%
- Net Margin
- -1864.12%
- ROE
- -134.65%
- ROIC
- -108.88%
- Revenue
- $4.40M · -11.53%
- Net Income
- $-69,021,612 · 53.89%
- EPS
- $-0.32 · 55.56%
- Op Income
- $-70,940,449
- FCF YoY
- 17.25%
- 52W High
- $0.34
- 52W Low
- $0.06
- 50D MA
- $0.09
- 200D MA
- $0.17
- Beta
- 2.14
- Avg Volume
- 19.37K
Get TickerSpark's AI analysis on IUGNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IUGNF coverage
Recent articles, reports, and earnings notes.
No research on IUGNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IUGNF report →Similar companies
Peers in the same neighborhood.